Roche

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

Retrieved on: 
Sunday, April 7, 2024
BNTX, Survival, Entrepreneurship, Genentech, Disease, BioNTech, Patient, Neoplasm, Tissue, Messenger, PDAC, Roche, Uridine, Safety, Cancer, De novo, Recurrence, Blood, Vaccine

The data show that in 8 out of 16 patients autogene cevumeran elicited an immune response up to three years post administration measured by activated T cells.

Key Points: 
  • The data show that in 8 out of 16 patients autogene cevumeran elicited an immune response up to three years post administration measured by activated T cells.
  • The persistence of T cels was associated with a longer median recurrence-free survival in cancer vaccine responders.
  • “These new data are an early signal for the potential of our individualized mRNA cancer vaccine approach in this indication with an unmet medical need.
  • Over 80% of the vaccine-induced neoantigen-specific T cells could still be detected up to three years post administration in patients with an immune response.

NeuroVigil, World’s Most Valuable Neurotech, Launches iBrain™ in US

Retrieved on: 
Friday, April 5, 2024
Head, Roche, MIT Technology Review, IP, FCCP, Clinic, Seed, Consciousness, Partnership, Novartis, SAN, DNA, Aneurysm, Critical care, Stanford School, Cedars-Sinai Medical Center, Lawyer, Harvard Medical School, DSS, University, MD, Hospital, FDA, Apnea, Brain, ALS, MIT, Neocortex, Biomarker, Bird, Doctor of Philosophy, Human, Brain tumor, BCIS, Silicon, Patent, VCS, Division

The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.

Key Points: 
  • The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.
  • A joint abstract by Dr. Low and Dr. Hawking featuring Dr. Hawking’s brain patterns analyzed by NeuroVigil’s technology was released as early as 2012.
  • The technology was also successfully demonstrated on ALS sufferer Augie Nieto in 2013 who spelled “COMMUNICATE” with his mind.
  • In the past two years, NeuroVigil has recruited talent from Amgen, Roche, Novartis and MIT in preparation for the launch.

CORRECTION -- NeuroVigil, World’s Most Valuable Neurotech Company, Launches in US

Retrieved on: 
Friday, April 5, 2024
Head, Roche, MIT Technology Review, IP, FCCP, Clinic, Seed, Consciousness, Partnership, Novartis, SAN, DNA, Aneurysm, Critical care, Stanford School, Cedars-Sinai Medical Center, Lawyer, Harvard Medical School, DSS, University, MD, Hospital, FDA, Apnea, Brain, ALS, MIT, Neocortex, Biomarker, Bird, Doctor of Philosophy, Human, Brain tumor, BCIS, Patent, VCS, Division

“Who needs implants when you have the real deal?” said Dr. Philip Low, PhD, NeuroVigil’s Chairman, Chief Executive and Technology Officer, Founder and Supermajority Owner.

Key Points: 
  • “Who needs implants when you have the real deal?” said Dr. Philip Low, PhD, NeuroVigil’s Chairman, Chief Executive and Technology Officer, Founder and Supermajority Owner.
  • The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.
  • The technology was also successfully demonstrated on ALS sufferer Augie Nieto in 2013 who spelled “COMMUNICATE” with his mind.
  • In the past two years, NeuroVigil has recruited talent from Amgen, Roche, Novartis and MIT in preparation for the launch.

NeuroVigil, World’s Most Valuable Neurotech Company, Launches in US

Retrieved on: 
Friday, April 5, 2024
Head, Roche, MIT Technology Review, IP, FCCP, Clinic, Seed, Consciousness, Partnership, Novartis, SAN, DNA, Aneurysm, Critical care, Stanford School, Cedars-Sinai Medical Center, Lawyer, Harvard Medical School, DSS, University, MD, Hospital, FDA, Apnea, Brain, ALS, MIT, Neocortex, Biomarker, Bird, Doctor of Philosophy, Human, Brain tumor, BCIS, Silicon, Patent, VCS, Division

The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.

Key Points: 
  • The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.
  • A joint abstract by Dr. Low and Dr. Hawking featuring Dr. Hawking’s brain patterns analyzed by NeuroVigil’s technology was released as early as 2012.
  • The technology was also successfully demonstrated on ALS sufferer Augie Nieto in 2013 who spelled “COMMUNICATE” with his mind.
  • In the past two years, NeuroVigil has recruited talent from Amgen, Roche, Novartis and MIT in preparation for the launch.

Cannabix Technologies Welcomes Dr. Phillip Olla to the Board of Directors

Retrieved on: 
Tuesday, April 2, 2024
MIS, Brunel University London, Management information system, University of Detroit Mercy, Research, United Nations, University, IBM, Health, Morgan Stanley, Doctor of Philosophy, BT Group, Publication, Roche, World Health Organization, OTC, Telecom, Book, THC, Blood, Consultant, Medical device

VANCOUVER, British Columbia, April 02, 2024 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of marijuana and alcohol breath testing devices is pleased to report that Dr. Phillip Olla (Ph.D.) has joined the board of directors.

Key Points: 
  • VANCOUVER, British Columbia, April 02, 2024 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of marijuana and alcohol breath testing devices is pleased to report that Dr. Phillip Olla (Ph.D.) has joined the board of directors.
  • Dr. Olla is an expert in breath technologies, breathomics, healthcare innovation, artificial and medical informatics.
  • Dr. Olla is one of only a handful of scientists globally who has ever conducted delta-9 THC analysis in blood and breath.
  • Dr. Olla is an associate professor at University of Detroit Mercy in Michigan and is the Vice Chair of the MedHealth Consortium.

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, March 29, 2024
Head, Immunotherapy, HNSCC, Patient, Roche, Lead, Immunoglobulin G, Neoplasm, CRC, Audit committee, PD-1, Observation, Bioinformatics, Colorectal cancer, SAN, Information technology, Pembrolizumab, PRS, Safety, PD-L1, Compensated emancipation, Annual report, Apoptosis, Cervical cancer, Part, Merck, Senior, Bevacizumab, MSS, GAAP, ASCO, PFS, MTD, Liver disease, HCC, Therapeutic index, Endometrial cancer, Progression-free survival, ADS, Net, Regulatory T cell, Research and development, Liver, Pharmaceutical industry

SAN DIEGO and SUZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today reported financial results for the full year 2023 and provided corporate updates.

Key Points: 
  • Both confirmed PRs are sustained after more than one year with repeat dosing while maintaining robust safety profiles.
  • Observation of these clinical activities triggered further expansion into the second stage of the Simon’s 2-stage design for this dose level.
  • Net loss attributable to Adagene Inc.’s shareholders was US$18.9 million for the year ended December 31, 2023, compared to US$80.0 million in 2022.
  • The company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure.

Healis Therapeutics announces collaboration with Massachusetts General Hospital (MGH) and affiliates of Harvard Medical School to advance clinical-stage neuroscience research

Retrieved on: 
Tuesday, March 26, 2024
MGH, Harvard Medical School, Public health, Mass General Brigham, Massachusetts General Hospital, MDD, Patient, Public, Roche, Research, Merck, Social anxiety disorder, DSM-IV codes, Bristol Myers Squibb, Clinical trial, Neuropsychiatry, HMS, World Health Organization, Therapy, Hospital, Safety, WHO, SAD, Major depressive disorder, PTSD, Mass, Pharmaceutical industry

Healis Therapeutics is pleased to announce that it has entered a clinical collaboration with Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham health system, and affiliates of Harvard Medical School (HMS).

Key Points: 
  • Healis Therapeutics is pleased to announce that it has entered a clinical collaboration with Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham health system, and affiliates of Harvard Medical School (HMS).
  • “We continue to observe very significant need in the neuropsychiatric patient population,” said Dr. Eric Finzi, Co-Founder of Healis Therapeutics.
  • “MDD remains a public health challenge around the world,” said Erik Van Widenfelt, Head of Clinical Trials at Healis Therapeutics.
  • General Hospital (MGH) and Harvard Medical School,” said Sebastian De Beurs, Co-Founder of Healis Therapeutics.

Welcome to TeKnowledge: Accelerating Progress. Securing Futures.

Retrieved on: 
Tuesday, April 9, 2024
Consulting, Data Management, Technology, Professional Services, Security, Other Technology, Telecommunications, Software, Networks, Internet, Hardware, Transfer, Microsoft, Organization, Growth, Roche, CISO, Ria Money Transfer, Aileen, MSS, Fortune 500, Managed security service, Multimedia, Government, HP, Management

Under the guidance of Aileen Allkins, President and CEO, TeKnowledge is pioneering new frontiers in digital services.

Key Points: 
  • Under the guidance of Aileen Allkins, President and CEO, TeKnowledge is pioneering new frontiers in digital services.
  • Their collective skills in global operations, cybersecurity, digital transformation, and customer experience, honed over decades, are crucial in navigating the digital landscape's complexities.
  • Our approach integrates these services seamlessly, maximizing efficiency, simplifying processes, and accelerating the achievement of strategic imperatives with unparalleled precision and efficacy."
  • Dynamic Cybersecurity Services: With an all-encompassing suite of advisory and Managed Security Services (MSS) offerings, TeKnowledge (f.k.a.

Sepsis Diagnostics Market Worth $890 million | MarketsandMarkets™.

Retrieved on: 
Monday, April 8, 2024
Sepsis, High, Development, Growth, Fungal infection, Abbott Laboratories, Incidence, Thermo Fisher Scientific, Danaher Corporation, Biomarker, Sysmex Corporation, Evolution, Pulse, Roche, Service, Vanderbilt University Medical Center, EKF Diagnostics, Medical device

Key Market Players of Sepsis Diagnostics Industry:

Key Points: 
  • Key Market Players of Sepsis Diagnostics Industry:
    As of 2023, prominent players in sepsis diagnostics are bioMérieux (France), Becton Dickinson Company (US), Danaher Corporation (US), Abbott Laboratories (US), and Roche Diagnostics (Switzerland).
  • Other players include T2 Biosystems (US), Thermo Fisher Scientific (US), Bruker (US), EKF Diagnostics (UK), Immunexpress (Australia), among others.
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=92673155
    Sepsis Diagnostics Market - Key Benefits of Buying the Report:
    The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share.
  • Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.

Sepsis Diagnostics Market Worth $890 million | MarketsandMarkets™.

Retrieved on: 
Monday, April 8, 2024
Sepsis, High, Development, Growth, Fungal infection, Abbott Laboratories, Incidence, Thermo Fisher Scientific, Danaher Corporation, Biomarker, Evolution, Pulse, Roche, Service, Vanderbilt University Medical Center, EKF Diagnostics, Medical device

Key Market Players of Sepsis Diagnostics Industry:

Key Points: 
  • Key Market Players of Sepsis Diagnostics Industry:
    As of 2023, prominent players in sepsis diagnostics are bioMérieux (France), Becton Dickinson Company (US), Danaher Corporation (US), Abbott Laboratories (US), and Roche Diagnostics (Switzerland).
  • Other players include T2 Biosystems (US), Thermo Fisher Scientific (US), Bruker (US), EKF Diagnostics (UK), Immunexpress (Australia), among others.
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=92673155
    Sepsis Diagnostics Market - Key Benefits of Buying the Report:
    The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share.
  • Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.